Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects by Ryu, Rachel & Ward, Kristina E.
University of Rhode Island
DigitalCommons@URI
Pharmacy Practice Faculty Publications Pharmacy Practice
2018
Atezolizumab for the First-Line Treatment of Non-
small Cell Lung Cancer (NSCLC): Current Status
and Future Prospects
Rachel Ryu
University of Rhode Island, rachel_ryu@my.uri.edu
Kristina E. Ward
University of Rhode Island, kward@uri.edu
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs
This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in
Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Ryu R and Ward KE (2018) Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and
Future Prospects. Front. Oncol. 8:277. doi: 10.3389/fonc.2018.00277
Available at: https://doi.org/10.3389/fonc.2018.00277
REVIEW
published: 24 July 2018
doi: 10.3389/fonc.2018.00277
Frontiers in Oncology | www.frontiersin.org 1 July 2018 | Volume 8 | Article 277
Edited by:
Yanis Boumber,
Fox Chase Cancer Center,
United States
Reviewed by:
Iacopo Petrini,
Scuola Sant’Anna di Studi Avanzati,
Italy
Anish Thomas,
National Cancer Institute (NCI),
United States
*Correspondence:
Rachel Ryu
rachel_ryu@my.uri.edu
Specialty section:
This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology
Received: 26 March 2018
Accepted: 03 July 2018
Published: 24 July 2018
Citation:
Ryu R and Ward KE (2018)
Atezolizumab for the First-Line
Treatment of Non-small Cell Lung
Cancer (NSCLC): Current Status and
Future Prospects.
Front. Oncol. 8:277.
doi: 10.3389/fonc.2018.00277
Atezolizumab for the First-Line
Treatment of Non-small Cell Lung
Cancer (NSCLC): Current Status and
Future Prospects
Rachel Ryu* and Kristina E. Ward
Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, United States
Purpose: Atezolizumab is a programmed death ligand 1 (PDL-1) blocking antibody
that was approved for metastatic non-small cell lung cancer (NSCLC) in patients with
disease progression. Various studies have been initiated to explore the effectiveness
of atezolizumab among different patient cohorts and disease statuses, including as
first-line therapy. The purpose of this paper is to identify and summarize the trials that
use atezolizumab as a first-line agent in chemotherapy-naïve patients with NSCLC.
Methods: A database search was performed on Pubmed, Embase, andWiley Cochrane
Library—Central Register of Controlled Trials to identify clinical trials using atezolizumab
as first-line therapy in NSCLC. Additionally, ClinicalTrials.gov and the International
Clinical Trials Registry Platform (ICTRP) were searched to identify relevant clinical trials.
Conference abstracts from the American Society of Clinical Oncology, the European
Society for Medical Oncology, and the American Association for Cancer Research
were hand-searched. Any trial in which atezolizumab was used as first-line therapy in
chemotherapy-naive patients with NSCLC was included.
Results: Fifteen studies were ultimately included, all of which are current and ongoing. Of
the 15 studies, 5 have reported results. When given in the first-line setting, atezolizumab
had higher rates of objective response, progression-free survival, and overall survival,
compared to the second and third-line settings. Among the 15 studies, atezolizumab is
used as monotherapy (n = 5), in combination with chemotherapy (n = 6), in combination
with targeted therapy such as bevacizumab (n = 1), as neoadjuvant/adjuvant therapy
(n = 3), in combination with stereotactic body radiation therapy (n = 1), and in
combination with or following chemoradiation (n = 1).
Conclusion: Available evidence shows promising safety and efficacy with the use of
atezolizumab as first-line therapy in NSCLC. Atezolizumab is currently being studied in
a variety of treatment settings. If clinical benefits are shown, atezolizumab may deem to
be a useful first-line agent in NSCLC.
Keywords: immunotherapy, targeted therapy, non-small cell lung cancer, squamous cell cancer, large cell
carcinoma, adenocarcinoma
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INTRODUCTION
The levels of activity, response, and differentiation of T cells
are largely regulated by positive and negative effects on the
costimulatory pathways (1). Activation of T cells occurs when
the co-stimulatory molecules, B7-1 and B7-2, bind to the CD28
receptor (2). T cells are inhibited when the B7-1 and B7-2
molecules bind to the cytotoxic T cell lymphocyte antigen 4
(CTLA-4). Inhibition also occurs when other ligands of the same
B7 family, B7H1 (PDL-1) and B7-DC (PDL-2), bind to the PD-
1 receptor (1, 2). B7H-1 is predominately found in tumors cells
and rarely in human tissue (3). Therefore, when tumor-associated
B7H-1 molecules bind to PD-1 receptors on activated T cells, T
cells undergo apoptosis, thereby disabling the immune system
from actively killing tumor cells (3, 4).
Atezolizumab is a PDL-1 inhibitor that was designed to
restore anti-tumor action by preventing the immunosuppression
caused by the B7H-1 and the PD-1 interaction (5). Atezolizumab
was approved by the Food and Drug Administration (FDA) in
October 2016 for the treatment of metastatic non-small cell lung
cancer (NSCLC) in patients whose disease progressed during
or following traditional platinum-based therapy, or targeted
therapy in patients harboring the epidermal growth factor
receptor (EGFR)mutation or anaplastic lymphoma kinase (ALK)
fusion. Approval was based on the findings of the POPLAR and
OAK trials, which administered atezolizumab for the second-
line treatment of advanced NSCLC, and longer rates of overall
survival were shown (6, 7).
The status of atezolizumab in comparison to other immune
checkpoint inhibitors employing the PDL-1 signaling pathway is
worth noting. Pembrolizumab is approved as first-line therapy
for patients with NSCLC expressing over 50% PDL-1 expression,
whereas nivolumab is limited for use in patients with metastatic
NSCLC or disease progression. Durvalumab is indicated for
use in patients with unresectable stage III NSCLC following
chemoradiation with no signs of disease progression. Lastly,
avelumab has not yet been approved for use in NSCLC, though
research is ongoing. In a phase 1b trial of 145 patients with
advanced NSCLCwithout the EGFRmutation or ALK fusion and
not preselected for PDL-1 expression, improved response rates
were seen with avelumab as first-line therapy (8). The results
of a phase III trial comparing first-line avelumab to standard
chemotherapy in patients with NSCLC is pending. The objective
of this paper is to identify and summarize all trials that use
atezolizumab as a first-line agent in chemotherapy-naïve patients
with NSCLC.
MATERIALS AND METHODS
This paper was conducted in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines and was prospectively registered with
PROSPERO (registration number: CRD42017069416). A
database search was performed on Pubmed (1946–2017),
Embase (1947–2017), and Wiley Cochrane Library—Central
Register of Controlled Trials (1898–2017) to search for clinical
trials using atezolizumab as first-line therapy in NSCLC. Search
strategies included controlled vocabulary and terms such as
“nonsmall cell lung cancer,” “squamous cell cancer,” “large
cell carcinoma,” and “adenocarcinoma.” Limits on year were
not placed and studies were limited to English. Additionally,
ClinicalTrials.gov and the International Clinical Trials Registry
Platform (ICTRP) were searched to identify relevant clinical
trials. Databases and clinical trial registries were last searched on
5/17/17. An example of the search strategy for Pubmed is shown
in Appendix 1. Journals such as the American Society of Clinical
Oncology (2004—present), the European Society for Medical
Oncology (2004—present), and the American Association for
Cancer Research (2004—present) were last accessed on 5/22/18.
RESULTS
A total of 561 records were identified from all sources and
duplicates were subsequently removed. The remaining studies
were screened for relevancy and of those, 459 studies were
excluded. Thirty-four studies were reviewed in full text and
15 studies were ultimately included (Figure 1). Among the 15
ongoing studies, 5 have reported results (Table 1).
Studies of Atezolizumab as First-Line
Therapy With Results
The five studies with results are phase 1b (n= 1), phase II (n= 3),
and phase III (n= 1) trials. Endpoints are measured according to
the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
criteria (9).
A Study of Atezolizumab Administered in
Combination With Bevacizumab and/or With
Chemotherapy in Participants With Locally Advanced
or Metastatic Solid Tumors (NCT01633970)
In the phase 1b study, atezolizumab was administered in
combination with chemotherapy to patients with various tumors
(10). Arms A, B, and F included gastric cancer, ovarian cancer,
bladder cancer, cervical cancer, and breast cancer. Arms C, D, and
E comprised of patients with NSCLC (Table 1). Atezolizumab
was administered as maintenance therapy for all arms until
disease progression or intolerable toxicity.
Standard chemotherapy doses were used in ≤6 cycles and
atezolizumab was dosed at 15 mg/kg intravenously (IV) every 3
weeks to determine the maximum tolerated dose (MTD), which
was to be used in the dose expansion cohort. Primary outcomes
included the MTD, percentage of participants with adverse
events (AEs), and percentage of patients with dose-limiting
toxicities (DLTs). Secondary outcomes included duration of
objective response rate (ORR), progression-free survival (PFS),
and the pharmacokinetics of atezolizumab such as clearance,
volume of distribution, accumulation ratio, and half-life. The goal
enrollment for all arms was 240 patients.
Patient demographics were provided initially for the safety
evaluable population but not in the efficacy evaluable population
(n = 76) (10, 11). Among the patients that were evaluated,
the confirmed ORR was the highest in arm D, although the
medians and confidence intervals were not provided. Further,
Arm D demonstrated the highest median PFS and median
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FIGURE 1 | Screening and eligibility evaluation phases.
overall survival (OS). For adverse effects (AEs), neutropenia and
anemia were the most prominent. In arms C, D, and E, 36–
42% had neutropenia and 16–31% had anemia. Cases of grade 5
pneumonia, systemic candida, and autoimmune hepatitis in arm
E were isolated.
Overall, an interdependent relationship between
chemotherapy and immunotherapy was inferred, based on
favorable results seen when atezolizumab was given with
chemotherapy. Previously, a synergistic effect was seen when
pembrolizumab was combined with pemetrexed-carboplatin
(12). Despite small enrollment numbers, the study findings led
to the initiation of a phase III program—IMpower 130, 131, 132,
and 150 (13).
BIRCH (NCT02031458)
BIRCH was a phase II, single-arm study that administered
atezolizumab in the first- (cohort 1), second- (cohort 2), and
third-line (cohort 3) settings in the treatment of advanced
NSCLC in patients with a minimum of 5% PDL-1 expression
on both tumor cells (TC2/3) and tumor-infiltrating immune
cells (IC23), as determined by immunohistochemistry. Patients
in cohort 1 had not received previous chemotherapy (in either
the locally advanced or metastatic settings). Patients in cohort
2 did receive a platinum-based chemotherapy regimen and
progressed, while those in cohort 3 had progressed upon
at least two agents. For all three cohorts, atezolizumab was
administered at a dose of 1,200mg IV every 3 weeks until
disease progression, unacceptable toxicity, or death. Patients in
cohorts 2 and 3 were permitted to continue therapy as long
as signs of disease progression and tumor growth were absent,
a decline in Eastern Cooperative Oncology Group (ECOG)
score was not observed, and clinical benefit was perceived. The
primary outcome was the percentage of patients that obtained
an independent review facility (IRF)-assessed ORR. Secondary
outcome measures included investigator (INV)-assessed ORR as
determined by both RECIST v1.1 andmodified RECIST, duration
of response (DOR), PFS, and OS. [When the unmodified and
modified RECIST v1.1 criteria were used in various tumors, the
difference inmeasurements were<10% and tumor response rates
were not statistically significant (14)].
A total of 667 patients were enrolled into the study. Patients
with central nervous system (CNS) disease, including metastases,
were excluded. Presence of the EGFR mutation or ALK fusion
was permitted if previous therapy with a tyrosine-kinase inhibitor
was given. The median age was 67 years (range 35–88) in cohort
1, 63 years (range 28–83) in cohort 2, and 64 years (range 38–
84) in cohort 3. Men comprised 51% of patients in cohort 1, and
61% in cohorts 2 and 3. The proportion of current or previous
tobacco users was similar among the cohorts and ranged from
82 to 84%. The predominant race and histology were white and
nonsquamous.
Among the three cohorts, patients in cohort 1 had the highest
ORR, median PFS, and median OS (Table 1). When patients
with high PDL-1 expression (TC3/IC3) were analyzed, all three
measures were the highest in cohort 1 as well. Patients that were
previous or current tobacco users and those with nonsquamous
histology had the highest response rates. In cohort 1, ORR
was achieved by 19% (95% CI, 12–28) in patients that tested
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TABLE 1 | Current trials with results.
Identifier, phase Disease Intervention Results
Efficacy
analysis
ORR PFS (months) OS (months)
NCT01633970b
1b
IIIB, IV,
or
recurrent
NSCLC
Arms A, B, F*
Arm C: Atez +
PC
Arm D: Atez +
Pem-Cb
Arm E: Atez +
nab-PC
C: n = 25
D: n = 25
E: n = 26
C: 36%
D: 64% (1 CR)
E: 46% (4 CR)
C: 7.1 (95% CI, 4.2–8.3)
D: 8.4 (95% CI, 4.7–11)
E: 5.7 (95% CI, 4.4–14.8)
C: 12.9 (95% CI, 8.8-NE)
D: 19.3 (95% CI,
14.7–27.4)
E: 14.7 (95% CI, 4.4–14.8)
NCT02031458b
(BIRCH) II
PDL-1
positive, IIIB,
IV,
or
recurrent
NSCLC
1L: Atez
monotherapy
2L: Atez
monotherapy
3L: Atez
monotherapy
1L: n = 139
2L: n = 268
3L: n = 252
1L: 22% (95% CI, 15–29)
2L: 19% (95% CI, 15–25)
3L: 18% (95% CI, 13–23)
1L**: 5.4 (95% CI, 3–6.9)
2L
†
: 2.8 (95% CI, 1.5–3.9)
3L
†
: 2.8 (95% CI, 2.7–3.0)
1L: 23.5 (95% CI, 18.1-NE)
2L: 15.5 (95% CI,
12.3–19.3)
3L: 13.2 (95% CI,
10.3–17.5)
NCT01846416b
(FIR) II
PDL-1
positive, IIIB,
IV,
or
recurrent
NSCLC
1L: Atez
monotherapy
2L: Atez
monotherapy
3L: Atez
monotherapy
1L: n = 31
2L: n = 71
3L: n = 12
1L***: 29% (95% CI,
13–45)
2L
†
: 17% (95% CI, 8–26)
3L: 17% (95% CI, 0–38)
N/A N/A
NCT02525757a II Non-
metastatic,
unresectable
NSCLC
Group 1: PC +
XRTX, then atez
Group 2: PC +
XRTX + atez
N/A
††
N/A N/A N/A
NCT02366143c
(IMpower150) III
IV non-
squamous
NSCLC
Arm A: Atez+PC
Arm B:
Atez+PC+bev
Arm C: PC+bev
A
†††
B: 356
C: 336
B***: 64% (95% CI, 58, 68)
C***: 48% (95% CI, 43, 54)
B: 8.3 (95% CI, 7.7, 9.8)
C: 6.8 (95% CI, 6.0, 7.1)
N/A
Bolded items represent atezolizumab as first-line therapy.
aCurrently recruiting participants.
bNot yet open for recruiting participants.
cNot currently recruiting participants; *Not NSCLC; **IRF-assessed; ***Unconfirmed ORR;
†
Confirmed ORR;
††
Only safety data were reported;
†††
Data only available for Arms
B and C. 1L, cohort 1, atezolizumab as first-line therapy; 2L, cohort 2, atezolizumab as second-line therapy; 3L, cohort 3, atezolizumab as third-line therapy; AEs, adverse events;
atez, atezolizumab; bev, bevacizumab; CR, complete remission; DLT, dose-limiting toxicities; INV, investigator; IRF, independent review facility; nab-PC, nab-paclitaxel, carboplatin; NE,
not evaluable; NSCLC, non-small cell lung cancer; ORR, objective response rate; PC, paclitaxel, carboplatin; Pem-Cb, pemetrexed-carboplatin; RECIST, Response Evaluation Criteria
in Solid Tumors; XRTX, radiation therapy.
negative for the EGFR mutation (n = 104) and 23% (95%
CI, 5–54) in patients that tested positive (n = 13). Similarly,
a previous durvalumab trial showed improvement in objective
response among patients with advanced NSCLC, ≥25% PDL-
1 expression, and with the EGFR mutation or ALK fusion
(15).
Further, of the 100 patients analyzed for Kirsten rat sarcoma
(KRAS) mutation status in cohort 1, ORR was seen in 27% (95%,
13–46) of patients with the mutation and 16% (95%, 8–27) of
patients without the mutation. Cohorts 2 and 3 also showed high
ORRs and median PFS for patients regardless of mutation status.
The most predominant AEs in all patients were fatigue (19%),
diarrhea (11%), and nausea (11%). The total number of AEs
and treatment-related AEs were comparable across the cohorts
and occurred regardless of PDL-1 expression. AEs that led to
the discontinuation of atezolizumab included pneumonitis and
pneumonia in 8 patients in cohort 1 (n = 139, 6%), 20 patients
in cohort 2 (n = 268, 8%), and 15 patients in cohort 3 (n = 252,
6%). In total, 43 patients (7%) discontinued treatment and 305
deaths (46%) occurred, with 90% of the deaths being attributed
to disease progression (16).
FIR (NCT01846416)
Like BIRCH, FIR was a phase II, single-arm study that
administered atezolizumab as first (cohort 1), second (cohort
2), and third-line (cohort 3) therapy in NSCLC among patients
with a minimum PDL-1 expression of 5% (TC2/3 or IC2/3).
Cohort 1 constituted patients with no history of chemotherapy
in the advanced setting, cohort 2 had patients who progressed
during or after a platinum-based regimen, and cohort 3 included
patients with progression after an unrestricted number of
previous therapies, as well as patients with asymptomatic brain
metastases. A total of 138 patients were enrolled in the study
and atezolizumab was dosed at 1,200mg IV every 3 weeks
until disease progression. Cohorts 2 and 3 received therapy
until investigators did not perceive any clinical benefit. The
Frontiers in Oncology | www.frontiersin.org 4 July 2018 | Volume 8 | Article 277
Ryu and Ward Atezolizumab for the 1L Treatment of NSCLC
primary outcome was the INV-assessed ORR according to the
modified RECIST v1.1 criteria. Secondary outcomes included
INV-assessed ORR, DOR, and percentage of patients with 6-
month DOR.
The median age was 66 years, with the range being from 42
to 85. Of all patients, 58% were men. All patients who received
at least one dose of atezolizumab were evaluated for efficacy
(n = 114). The highest ORRs were seen in cohort 1. Of those
that responded, the range in DOR was 7–30% in cohort 1 and
11–69% in cohort 2. The median PFS and median OS were not
reported, although the 6-month PFS was seen in 39% (95% CI,
22–56) of patients in cohort 1 and 35% (95% CI, 23–46) in
cohort 2. The most common treatment-related AEs were fatigue
(26%) and nausea (15%), which were considered manageable
and tolerable. Grade 3–4 AEs were seen in 15% of patients and
included elevated hepatic enzymes, hypertension, and pulmonary
embolism. Single cases of Guillian-barre syndrome, diabetes,
pneumonitis, and disseminated herpes zoster were reported.
Grade 5 AEs occurred in 10 cases, which included cardiac
arrest, disseminated intravascular coagulation, and constrictive
pericarditis (17).
Based on this data, patients with asymptomatic brain
metastases (cohort 3) did respond, though least favorably
compared to patients without brain metastases. Previously, in
patients with NSCLC and brain metastases, nivolumab showed
safety and clinical efficacy, and pembrolizumab demonstrated an
acceptable safety profile (18, 19).
Atezolizumab With Chemoradiation for Lung Cancer
(NCT02525757)
A phase II study was designed to evaluate the response to
atezolizumab following, as well as in combination with,
chemoradiation (10). The integration of chemoradiation
in immunotherapy regimens has been demonstrated in
trials with pembrolizumab and nivolumab. This technique
is attempted in patients with medically inoperable
tumors.
In this trial, Group 1 completed treatment and Group 2 is in
the process of patient recruitment (Table 1). Eligible patients had
disease that was considered unresectable and non-metastasized
with no previous history of chemotherapy. The primary outcome
is the time to toxicity, defined as any grade 3 or 4 AE in the
first 15 weeks of therapy or any immune-related adverse events
(irAEs). The secondary outcome is the PFS at 6 months and
1 year.
Group 1 received atezolizumab 1,200mg every 3 weeks
for up to 14 doses as consolidation therapy after first-line
chemoradiation. Standard doses of carboplatin and paclitaxel
were used, and radiation was given for 6–7 weeks. Three more
patients will be included in this group. Patients in Group 2 will
receive atezolizumab in combination with chemoradiation as
first-line therapy in approximately 30 patients. The atezolizumab
regimen for consolidation and maintenance therapy will mimic
that of group 1.
Of the patients that were evaluated for efficacy, 3 experienced
irAEs. Grade 3 AEs of arthralgia and dyspnea occurred as isolated
cases and disease progression in 2 patients. The AEs were noted
to be tolerable and manageable.
IMpower150 (NCT02366143)
The phase III study randomized chemotherapy-naïve patients
with stage IV non-squamous NSCLC to Arms A, B, or C
(Table 1). A total of 356 and 336 patients were enrolled into
Arms B andC, respectively, for intention-to-treat wild-type (ITT-
WT; EGFR or ALK negative). The primary outcomes were the
INV-assessed PFS and OS. Patients with active or untreated CNS
metastases or malignancies other than NSCLC within 5 years
were excluded. Atezolizumab was dosed at 1,200mg IV every 3
weeks.
Primary analyses were conducted for Arms B vs. C. The
median age was 63 years old and 60% were former smokers
in both arms. In arms B and C, 61 and 62% were male.
The hazard ratio for PFS in Arm B compared to C was
0.62 (95% CI: 0.52, 0.74; p < 0.0001) in the ITT-WT. The
median PFS in Arms B and C was 8.3 and 6.8 months,
respectively. Patients in Arm B had comparable treatment-
related serious AEs to Arm C (25 vs. 19%, respectively)
(20).
The design of this trial resembles that of KEYNOTE-
021, wherein one of the cohorts of patients with metastatic
or unresectable NSCLC received pembrolizumab with
chemotherapy and bevacizumab. Unfortunately, all patients
in this cohort (n = 25) were unable to complete treatment
because of disease progression or death. Since patients
in IMPOWER150 had less severe disease at baseline, the
trial showed the safety and efficacy of adding a checkpoint
inhibitor (atezolizumab) to bevacizumab and chemotherapy.
Additionally, nivolumab has been safely administered in
combination with chemotherapy and bevacizumab as
maintenance therapy in patients with advanced NSCLC
(21).
Studies of Atezolizumab as First-Line
Therapy Without Results
For the ten ongoing trials without results, atezolizumab 1,200mg
is administered IV every 3 weeks and the number of cycles is
trial-dependent. All studies employ the RECIST v1.1 criteria for
the measurement of outcomes. The studies are phase I (n = 1),
phase II (n= 4), and phase III (n= 5) trials (Table 2).
Atezolizumab and Stereotactic Body Radiation
Therapy in Treating Patients With Non-small Cell
Lung Cancer (NCT02599454)
A single-group phase I study is administering atezolizumab
in combination with stereotactic body radiation therapy
(SBRT) in stage I NSCLC to 33 patients who are not
medical or surgical candidates. Eligible patients must have a
tumor size ≤5 cm. During the dose escalation phase, patients
receive atezolizumab for 6 courses. After course 3, SBRT is
administered in 4–5 fractions. During the expansion phase,
atezolizumab and SBRT are given in a similar manner but
atezolizumab is continued until signs of toxicity or disease
progression. The primary outcome is the maximum tolerated
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TABLE 2 | Current trials without results.
Identifier, phase Disease Intervention Primary outcomes Estimated completion date
NCT02599454a
I
Medically/surgically inoperable I
NSCLC
Atez + SBRT Maximum tolerated dose November 2019
NCT02994576a
(PRINCEPS)
II
IB, II, or IIIA (non N2) NSCLC Atez as neoadjuvant therapy Rate of patients without major
toxicities or morbidities
May 2021
NCT03102242b
II
unresectable or inoperable IIIA/B
NSCLC
Atez as neoadjuvant therapy,
with CRT, and as adjuvant
therapy
DCR after 12 weeks induction Mar 2020
NCT02927301a
II
IB, II, or IIIA NSCLC Atez as neoadjuvant and
adjuvant therapy
Major pathologic response based on
surgical resection*
July 2023
NCT02848651a
(B-F1RST)
II
IIIB-IVB NSCLC Atez monotherapy INV-assessed ORR per modified
RECIST v1.1; PFS per RECIST v1.1
by circulating blood-based tumor
biomarkers
June 2020
NCT02409342a
(IMpower110)
III
PDL-1 positive, IV
non-squamous or squamous
NSCLC
Atez vs. chemotherapy OS August 2020
NCT02409355c
IMpower111)
III
PDL-1 positive, IV squamous
NSCLC
Atezo vs. chemotherapy INV-assessed PFS per RECIST v1.1 September 2017
NCT02367781c
(IMpower130)
III
IV non-squamous NSCLC (Atez + chemotherapy) vs.
chemotherapy
INV-assessed PFS per RECIST v1.1
(ITT and PDL-1-selected population);
OS (ITT and PDL-1-selected
population)
October 2018
NCT02367794c
(IMpower131)
III
IV squamous NSCLC (Atez + chemotherapy) vs.
chemotherapy
INV-assessed PFS per RECIST v1.1
(ITT and TGE population); OS (ITT
population)
February 2023
NCT02657434a
(IMpower132)
III
IV non-squamous NSCLC (Atez + chemotherapy) vs.
chemotherapy
INV-assessed PFS per RECIST v1.1;
OS
November 2019
aCurrently recruiting participants.
bNot yet open for recruiting participants.
cNot currently recruiting participants.
*Hellman et al., 2014. Atez, atezolizumab; AEs, adverse events; CRT, chemoradiotherapy; DCR, disease control rate; DLT, dose-limiting toxicities; IC1/2/3, tumor-infiltrating immune cells
with minimum 1% PDL-1 expression; IC2/3, tumor-infiltrating immune cells with minimum 5% PDL-1 expression; INV, investigator; IRF, independent review facility; ITT, intent-to-treat;
NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; SBRT,
stereotactic ablative radiotherapy; TC1/2/3, tumor cells with minimum 1% PDL-1 expression; TC2/3, tumor cells with minimum 5% PDL-1 expression; TGE, tumor gene expression.
atezolizumab dose that can be given concomitantly with
SBRT.
Previously, a case report showed that patients with
brain metastases responded better to nivolumab following
radiotherapy, compared to before (22). Further, in patients with
metastatic NSCLC, pembrolizumab in combination with SBRT
did not show an increase in toxicity (23). Based on previous
experience with other immune checkpoint inhibitors, the results
of this trial appear promising.
Atezolizumab as Induction Therapy in Non-small Cell
Lung Cancer (PRINCEPS) (NCT02994576)
In the single-arm,phase II study, atezolizumab is being
administered as neoadjuvant therapy in approximately 60
patients with stage 1B to IIIA (non N2) NSCLC. Eligible
patients must have disease that is considered resectable. Patients
receive atezolizumab as a one-time IV infusion. The primary
outcome is the rate of patients that do not experience major
toxicities or morbidities until 1 month following surgical
resection.
Atezolizumab Immunotherapy in Patients With
Advanced NSCLC (NCT03102242)
Patients with newly diagnosed and unresectable stage IIIA/B
NSCLC are receiving atezolizumab in combination with
chemoradiotherapy in a single-arm phase II pilot trial. An
estimated number of 63 patients are enrolled. Atezolizumab is
being administered in 4 cycles and patients will be re-staged
following the second and fourth cycles. If any signs of disease
progression occur after the second cycle, atezolizumab will be
discontinued and chemoradiotherapy initiated. The primary
outcome is the rate of disease control after 12 weeks of induction
therapy. Eligible patients will receive up to 1 year of adjuvant
therapy with atezolizumab. Previously, most patients with stage
III NSCLC safely received consolidation with pembrolizumab
following chemoradiation with low risk for serious pneumonitis
(24).
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A Study of Atezolizumab as Neoadjuvant and
Adjuvant Therapy in Stage IB, II, or IIIA Resectable
and Untreated Non-small Cell Lung Cancer (NSCLC)
(NCT02927301)
Approximately 180 patients with stage 1B to IIIA resectable
NSCLC are being given atezolizumab as neoadjuvant and
adjuvant therapy in a single-arm phase II trial (25). Eligible
patients must have adequate end-organ and hematologic
function. In the neoadjuvant setting, atezolizumab is being
given for 2 cycles and eligible patients continue to receive
adjuvant atezolizumab for up to a year. The primary outcome
is the major pathologic response following surgery, i.e. an
amount of viable tumor that is <10%. Note that following
neoadjuvant chemotherapy, patients with a viable tumor of
≤10% had longer OS and disease-free survival (DFS) compared
to those with ≥10% viable tumor (26). In a recent small study,
neoadjuvant nivolumab resulted in ≤10% viable tumor in 45%
of patients with resectable stage I-III NSCLC (n = 20) (27). It
is the expectation that atezolizumab would yield similar survival
benefits.
A Study of Atezolizumab as First-Line Monotherapy
for Advanced or Metastatic Non-small Cell Lung
Cancer (NSCLC): Clinical Evaluation of Novel
Blood-Based Diagnostics [B-F1RST] (NCT02848651)
Novel biomarker assays are being used instead of standard
tumor biopsies to measure PDL-1 expression in a single-arm,
phase II study (28). However, using PDL-1 as a biomarker is
controversial, as studies employ dissimilar criteria for detecting
PDL-1 positivity, as well as different methods for sample
collection and staining (29).
Approximately 150 patients with stage IIIB to IVB NSCLC
regardless of PDL-1 expression are being administered
atezolizumab as monotherapy until disease progression
or intolerable toxicity. Adequate end-organ function and
hematologic function are required. Patients with the EGFR
mutation or ALK fusion and active CNS metastases are excluded.
Co-primary outcomes include INV-assessed ORR and PFS based
on retrospective analysis of tumor biomarkers.
IMpower110, 111, 130, 131, and 132 (NCT02409342,
NCT02409355, NCT02367781, NCT02367794,
NCT02657434)
The IMpower trials are double-arm, open-label, phase III studies
that compare standard chemotherapy with atezolizumab as
monotherapy (IMpower110 and 111) or in combination with
standard chemotherapy (IMpower130, 131, and 132). Eligible
patients for all IMpower trials have stage IV NSCLC, an
ECOG score of 0–1, and adequate end organ function. Patients
receive atezolizumab until no clinical improvement or disease
progression, along with standard chemotherapy doses. The
primary endpoints are clinically relevant outcomes such as PFS
and OS.
All patients in IMpower110 and 111 have tumors that
are positive for PDL-1 expression. IMpower110 randomizes
patients with non-squamous histology in a one-to-one manner to
either atezolizumab or platinum-based chemotherapy containing
pemetrexed. Those with squamous histology are randomized
one-to-one to atezolizumab or platinum-based chemotherapy
with gemcitabine. IMpower111 is a smaller phase III trial
that is administering atezolizumab to patients exclusively with
squamous cell NSCLC. The drug and regimen are identical to
IMpower110 for this histology.
IMpower130, 131, and 132 are large phase III trials that are
comparing atezolizumab in combination with chemotherapy
to standard chemotherapy. IMpower130 assigns patients
two-to-one to either the experimental arm (platinum-based
chemotherapy in combination with atezolizumab) or the
comparator arm (standard platinum-based chemotherapy) (30).
IMpower131 uses the same regimen as IMpower130, with an
additional arm of nab-paclitaxel in the experimental group (13).
For maintenance therapy, atezolizumab is continued in the
experimental arm and best supportive care in the comparator
arm. The IMpower studies measure clinically relevant outcomes
such as PFS and OS as the primary endpoint and will ascertain
the role of atezolizumab in NSCLC.
DISCUSSION
Recently, the single-arm BIRCH trial showed high rates of
OS, PFS, and ORR for atezolizumab in chemotherapy-naïve
patients with at least 5% PDL-1 expression (16). In addition,
the smaller single-arm FIR trial also showed high ORR in
patients with a minimum of 5% PDL-1 expression when
given atezolizumab as first-line therapy, although the long-term
clinical benefits such as PFS and OS are not known yet (17).
Whether atezolizumab will gain approval for first-line therapy
in a similar fashion to pembrolizumab will be determined by
trials such as IMpower110 and 111, which will randomize
chemotherapy-naive patients to either atezolizumab or standard
platinum-based therapy in PDL-1 positive patients with NSCLC
(31).
When atezolizumab was given as first-line therapy in
combination with chemotherapy, impressive response rates were
seen (10). The highest ORR of 64% was seen in patients that
received atezolizumab with carboplatin and pemetrexed. In a
previous pembrolizumab trial, the ORR was 29% (95% CI, 18–
41) in patients that received carboplatin and pemetrexed, and
55% (95% CI, 42–68) in patients that received this regimen
in addition to pembrolizumab (12). However, it is evident
that direct comparisons cannot be made between the two
trials because of the use of different study methodologies and
unidentical patient populations. Most importantly, the phase 1b
atezolizumab study did not report interquartile ranges for the
results.
The mechanism for the possible synergy between PDL-
1 inhibitors and chemotherapy is not clear. In NSCLC,
chemotherapy decreased the level of PDL-1 expression on
tumor cells, and an increased level of PDL-1 expression
was shown to be an independent risk factor for decreased
overall survival (32, 33). However, discrepancies existed in
other cancers especially breast cancer (34). Chemotherapeutic
agents such as paclitaxel increased the expression of PDL-1,
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whereas doxorubicin decreased the expression of PDL-1 (34,
35).
The administration of atezolizumab after chemoradiation
was shown to be safe in patients with non-metastatic,
unresectable NSCLC (36). A previous study showed that
radiation could induce PDL-1 expression on cells, thereby
rendering PDL-1 inhibitors more effective (37). Thus,
chemoradiation may increase the potency of atezolizumab.
In the trials to come, atezolizumab will be administered as
neoadjuvant therapy in NSCLC as early as stage IB, and
as such, the patient population that could benefit from
atezolizumab may increase. Further, new blood-based biomarker
assays will be used to determine PDL-1 expression and
predict treatment response. If the assays denote accuracy
and reliability, tumor biopsies may not be necessary for
patients.
Overall, atezolizumab has shown a clinical benefit in the
first-line setting of NSCLC regardless of histology, PDL-1
expression, and EGFR or KRAS mutation status. High
rates of response and tolerability have been demonstrated.
Further evidence from ongoing and future trials will
precisely determine the role of atezolizumab in the treatment
of NSCLC.
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